Renfu Pharmaceutical (600079.SH) RFUS-949 tablets obtain approval for clinical trials.

Zhtng Cijng APP news, Renfu Medicine (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu") recently received the RFUS-949 tablet "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing the product to carry out clinical trials for acute and chronic pain.